AVTR vs. PFE: Avantor vs. Pfizer Stock Comparison

November 11, 2026

How do Avantor (AVTR) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Avantor (AVTR) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while PFE is classified in Pharmaceuticals.

Company profile comparison for Avantor (AVTR) and Pfizer (PFE)
Profile Item	AVTR	PFE
Name	Avantor, Inc.	Pfizer Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	10.48 billion USD	167.52 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	May 17, 2019	June 1, 1972
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

AVTR

PFE

GSPC

Avantor (AVTR) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Avantor (AVTR) and Pfizer (PFE). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Avantor (AVTR) and Pfizer (PFE). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
Total Return (1Y)	36.41%	28.65%
Total Return (3Y, Annualized)	-5.02%	6.41%
Total Return (5Y, Annualized)	-16.62%	-3.98%

Risk Profile

Drawdown History

AVTR

PFE

GSPC

Avantor (AVTR) vs. Pfizer (PFE), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Avantor (AVTR) and Pfizer (PFE). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
Volatility (1Y, Annualized)	43.39%	21.72%
Beta (5Y)	0.94	0.35
Max Drawdown (5Y)	-82.42%	-58.96%
Avg. Volume (3M)	8.56M	33.67M

Risk-Adjusted Performance

Risk-Return Positioning

AVTR and PFE are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
Sharpe Ratio (1Y)	0.74	1.12
Sortino Ratio (1Y)	1.17	1.73

Profitability

ROE (TTM)

Both Avantor (AVTR) at 5.91% and Pfizer (PFE) at 4.47% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.91%

Max: 109.18%
Q3: 6.23%
AVTR: 5.91%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.47%

Max: 109.18%
Q3: 6.23%
PFE: 4.47%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both Avantor (AVTR) at 5.08% and Pfizer (PFE) at 6.34% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.08%

Max: 18.05%
AVTR: 5.08%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.34%

Max: 18.05%
PFE: 6.34%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Pfizer (PFE) at 33.38% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 83.12%
Q3: 14.77%
AVTR: 8.19%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.38%

Max: 83.12%
PFE: 33.38%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
ROE (TTM)	5.91%	4.47%
ROA (TTM)	2.83%	5.59%
Net Margin (TTM)	5.08%	6.34%
Operating Margin (TTM)	8.19%	33.38%
Gross Margin (TTM)	31.59%	74.90%

Growth

Revenue Growth

Both Avantor (AVTR) at -3.41% and Pfizer (PFE) at -1.65% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their Revenue Growth across different time periods.

EPS Growth

Pfizer (PFE) at -3.55% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
Revenue Growth (YoY)	-3.41%	-1.65%
Revenue Growth (3Y CAGR)	-4.46%	-14.80%
EPS Growth (YoY)	-175.00%	-3.55%
EPS Growth (3Y CAGR)	--	-37.12%

Financial Strength

Current Ratio (MRQ)

Both Avantor (AVTR) at 1.89 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.89

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AVTR: 1.89
Min: 0.10

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.42

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
PFE: 1.42
Min: 0.10

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Avantor (AVTR) at 0.63 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.63

Max: 1.42
Q3: 0.65
AVTR: 0.63
Median: 0.15
Q1: 0.02
Min: 0.00

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71

Max: 1.42
PFE: 0.71
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
Current Ratio (MRQ)	1.89	1.42
Debt / Equity (MRQ)	0.63	0.71
Net Debt / EBITDA	3.40	1.97

Dividends

Dividend Yield (TTM)

Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.30%

PFE: 7.30%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Avantor (AVTR) pays no dividend (payout 0.00%).

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

AVTR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

245.71%

PFE: 245.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
Dividend Yield (TTM)	0.00%	7.30%
Dividend Payout Ratio (TTM)	0.00%	245.71%

Valuation

P/E Ratio (TTM)

Both Avantor (AVTR) at 30.94 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.94

Max: 85.34
Q3: 43.46
AVTR: 30.94
Median: 26.69
Q1: 13.30
Min: 0.07

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.99

Max: 85.34
Q3: 43.46
PFE: 41.99
Median: 26.69
Q1: 13.30
Min: 0.07

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Both Avantor (AVTR) at 1.58 and Pfizer (PFE) at 2.63 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.58

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
AVTR: 1.58
Min: 0.01

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
PFE: 2.63
Min: 0.01

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Avantor (AVTR) at 1.80 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.

AVTR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.80

Max: 13.53
Q3: 6.54
Median: 3.25
AVTR: 1.80
Q1: 1.69
Min: -5.59

PFE

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.88

Max: 13.53
Q3: 6.54
Median: 3.25
PFE: 1.88
Q1: 1.69
Min: -5.59

Avantor (AVTR) vs. Pfizer (PFE): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Avantor (AVTR) and Pfizer (PFE)
Metric	AVTR	PFE
P/E Ratio (TTM)	30.94	41.99
P/S Ratio (TTM)	1.58	2.63
P/B Ratio (MRQ)	1.80	1.88
Free Cash Flow Yield (TTM)	4.21%	7.76%